Maryam M Almulhem

Dr. Maryam M Almulhem

Respiratory therapy, King Faisal University, Al Hufūf, Ash Sharqīyah, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
IHIram Haq
Iram Haq
MAMaryam M Almulhem
Maryam M Almulhem
SSSimone Soars
Simone Soars
DPDavid Poulton
David Poulton
MBMalcolm Brodlie
Malcolm Brodlie
Cystic fibrosis (CF) is an autosomal recessive genetic condition that is caused by variants in the cystic fibrosis transmembrane conductance regulator gene. This causes multisystem disease due to dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel at the apical surface of epithelia. Until recently, treatment was directed at managing the downstream effects in affected organs, principally improving airway clearance and treating infection in the lungs and improving malabsorption in the gastrointestinal tract. Care delivered by multidisciplinary teams has yielded incremental improvements in outcomes. However, the development of small-molecule CFTR modulator drugs over the last decade has heralded a new era of CF therapeutics. Modulators target the underlying defect and improve CFTR function. Either monotherapy or a combination of modulators is used depending on the specific genotype and class of CFTR disease-causing variants that an individual has. Both ivacaftor and the ivacaftor/tezacaftor/elexacaftor combination have been demonstrated to be associated with clinically very significant benefits in randomised trials and have rapidly been made available as part of standard care in many countries. CFTR modulators represent one of the best examples of precision medicine to date. They are expensive, however, and equity of access to them worldwide remains an issue. Studies and approvals are also ongoing for children under the age of 6 years for ivacaftor/tezacaftor/elexacaftor. Furthermore, no modulators are available for around 10% of the people with CF. In this review, we firstly summarise the genetics, pathophysiology and clinical problems associated with CF. We then discuss the development of CFTR modulators and key clinical trials to support their use along with other potential future therapeutic approaches.

7 October 2022 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
MAMaryam M Almulhem
Maryam M Almulhem
NHNuala Harnett
Nuala Harnett
SGStephanie Graham
Stephanie Graham
IHIram Haq
Iram Haq
SVShelina Visram
Shelina Visram
MBMalcolm Brodlie
Malcolm Brodlie
Background: Cystic fibrosis (CF) is a genetic condition caused by variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that primarily impacts the lungs. Treatments historically have been symptomatic to improve airway clearance and treat infection. However, CFTR modulator drugs have recently been developed that target the underlying defect. The triple combination of elexacaftor-tezacaftor-ivacaftor (ETI) was approved in 2020 in England for over 80% of people with CF aged over 12 years and in 2022 extended to those over 6 years. ETI treatment is associated with substantial improvements in lung function. The experience of children with CF starting on ETI or their views regarding future treatments have not been well studied. This study aimed to explore the opinions of children with CF, their parents/carers and healthcare professionals (HCPs) on the impact of ETI, airway clearance techniques (ACTs) and nebulised treatments. Methods: Semistructured qualitative interviews were performed with 10 children with CF, 7 parents/carers and 10 HCPs. Audio recordings were transcribed and analysed using reflexive thematic analysis. Results: Four main themes were identified: ‘Kaftrio changed my life’, ‘Your entire life is dictated by the CF timetable’, ‘Simplifying treatment-hopes and fears’ and ‘Kaftrio is a game-changer’ along with several subthemes and an overarching theme of ‘I still can’t get my head around how three tablets can do what Kaftrio done’. Conclusions: Despite the highly positive impact of ETI on the health of children with CF some concerns remain about the longer-term outcomes of reducing ACTs or nebulised treatments. ETI has prompted a shift in treatment for many and offers an opportunity to personalise approaches.

15 August 2024 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
MAMaryam M Almulhem
Maryam M Almulhem
CWChronic Ward
Chronic Ward
IHIram Haq
Iram Haq
RGRobert D. Gray
Robert D. Gray
MBMalcolm Brodlie
Malcolm Brodlie
Background Pulmonary exacerbations (PExs) are clinically important in people with cystic fibrosis (CF). Multiple definitions have been used for PEx, and this scoping review aimed to identify the different definitions reported in the literature and to ascertain which signs and symptoms are commonly used to define them. Methods A search was performed using Embase, MEDLINE, Cochrane Library, Scopus and CINAHL. All publications reporting clinical trials or prospective observational studies involving definitions of PEx in people with CF published in English from January 1990 to December 2022 were included. Data were then extracted for qualitative thematic analysis. Results A total of 14 039 records were identified, with 7647 titles and abstracts screened once duplicates were removed, 898 reviewed as full text and 377 meeting the inclusion criteria. Pre-existing definitions were used in 148 publications. In 75% of papers, an objective definition was used, while 25% used a subjective definition, which subcategorised into treatment-based definitions (76%) and those involving clinician judgement (24%). Objective definitions were subcategorised into three groups: those based on a combination of signs and symptoms (50%), those based on a predefined combination of signs and symptoms plus the initiation of acute treatment (47%) and scores involving different clinical features each with a specific weighting (3%). The most common signs and symptoms reported in the definitions were, in order, sputum production, cough, lung function, weight/appetite, dyspnoea, chest X-ray changes, chest sounds, fever, fatigue or lethargy and haemoptysis. Conclusion We have identified substantial variation in the definitions of PEx in people with CF reported in the literature. There is a requirement for the development of internationally agreed-upon, standardised and validated age-specific definitions. Such definitions would allow comparison between studies and effective meta-analysis to be performed and are especially important in the highly effective modulator therapy era in CF care.

7 November 2025 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
AAAbdulelah Mastour Aldhahir
Abdulelah Mastour Aldhahir
MAMohammed M. Alyami
Mohammed M. Alyami
AAAhmed H. Alasimi
Ahmed H. Alasimi
AAAmirah M. Alqahtani
Amirah M. Alqahtani
RMRoaa E. Mousa
Roaa E. Mousa
HAHassan Alwafi
Hassan Alwafi
Diabetes mellitus (DM) predisposes individuals to respiratory tract infections (RTIs), making vaccination an essential preventive measure; however, evidence regarding vaccination awareness, uptake, and barriers among DM patients in Saudi Arabia is limited. This study aimed to assess the awareness, uptake, and barriers related to influenza, pneumococcal, and COVID-19 vaccinations among adults with DM in Saudi Arabia. A cross-sectional survey was conducted between December 2023 and March 2025 among 1,556 adults with type 1 and type 2 DM attending endocrinology clinics across three sites. A structured questionnaire evaluated awareness, uptake, and barriers, and data were analyzed using descriptive statistics and chi-square tests. Uptake rates were 60.8% for influenza, 88.7% for COVID-19, and 27.1% for pneumococcal vaccines, with pneumococcal vaccination lower in type 1 than type 2 DM (23.2% vs. 28.5%; p = .002) and COVID-19 vaccination higher in type 2 DM (90.1% vs. 84.6%; p = .001). Influenza infection was more common in type 2 DM (58.6% vs. 52.4%; p = .030), while pneumonia was less frequent in type 1 DM (10.2% vs. 16.3%; p = .003). Overall, 82.6% recognized the purpose of vaccination and 70.4% agreed that DM patients should be vaccinated, though misconceptions persisted, especially regarding pneumococcal vaccine efficacy. Healthcare providers were the main information source for influenza (45.6%) and pneumococcal vaccines (23.6%), while social media predominated for COVID-19 (49.1%). Despite reasonable awareness, vaccine uptake remains suboptimal, highlighting the need for targeted education and stronger healthcare provider engagement.

1 January 2026 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
RSRayan Siraj
Rayan Siraj
AAAhmed Alrajeh
Ahmed Alrajeh
MAMaryam M Almulhem
Maryam M Almulhem
MAMushabbab Alahmari
Mushabbab Alahmari
AAAbdulelah Mastour Aldhahir
Abdulelah Mastour Aldhahir
NANawaf Alsolami
Nawaf Alsolami
Background: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide. Evidence-based education is critical for improving healthcare professionals’ knowledge and promoting optimal clinical practice. However, no study has evaluated COPD-related knowledge among primary healthcare professionals in Saudi Arabia. Thus, this study aimed to assess the level of COPD knowledge in this group and to identify factors associated with higher scores. Methods: An online cross-sectional survey was conducted from October 2024 to May 2025 among licensed primary healthcare providers in Saudi Arabia, using the Bristol COPD Knowledge Questionnaire (BCKQ). One-way ANOVA was used to compare mean scores across demographic and professional groups, followed by multivariable linear regression to identify independent factors of knowledge. Results: A total of 1686 responses were received, of which 92 incomplete submissions were excluded, leaving 1594 fully completed questionnaires for analysis. Nurses accounted for 40.4%, general practitioners for 35.8%, and family medicine physicians for 24.0%. The mean (SD) total BCKQ score was 28.2 ± 8.15 out of 65 (43.4%), indicating moderate knowledge overall. The highest-scoring domain was Phlegm (2.96 ± 1.39), while the lowest was Inhaled Steroids (1.26 ± 0.86). Significant differences in knowledge were observed by profession (p = 0.004), region (p = 0.001), workplace (p < 0.001), clinic type (p < 0.001), prior COPD training (p = 0.010), and self-reported knowledge (p < 0.001). In multivariable linear regression, self-reported adequate knowledge (β = 3.99; p < 0.001), prior COPD training (β = 1.89; p = 0.011), and being a family medicine physician versus a general practitioner (β = 1.99; p = 0.027) were independently associated with higher knowledge. Conclusion: Primary healthcare professionals in Saudi Arabia showed moderate COPD knowledge, with gaps in prevention and pharmacological management. Higher scores were linked to prior COPD training, self-reported adequate knowledge, and being a family medicine physician. Expanding structured, evidence-based training could address these gaps and enhance COPD care nationwide.

15 February 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
RSRayan Siraj
Rayan Siraj
MAMaryam M Almulhem
Maryam M Almulhem
Background: Although burnout among respiratory therapists (RTs) is well documented, qualitative insights into their lived experiences in Saudi Arabia remain limited. This study explored RTs’ experiences of burnout, systemic and organisational drivers of professional strain, and strategies for resilience and retention within Saudi hospitals. Methods: A qualitative descriptive design was employed. Purposive sampling was used to recruit 11 RTs from diverse regions across Saudi Arabia. Semi-structured interviews were conducted in Arabic between September and November 2025, audio-recorded, and transcribed verbatim. Data management and analysis followed a hybrid approach using NVivo 12 software alongside manual coding to support deep immersion in the data. Analysis was guided by Braun and Clarke’s reflexive thematic analysis. Methodological rigour was enhanced through reflexive memoing, peer debriefing, and adherence to a 15-point trustworthiness checklist. Results: Analysis generated one overarching theme, “Caught Between Care and Collapse: The Human Cost of Institutional Burnout,” alongside three interrelated themes. Participants described (1) “Living within a system that drains the self,” highlighting sustained physical and emotional exhaustion driven by understaffing and extended shifts; (2) “Losing meaning and recognition,” illustrating how organisational neglect eroded professional passion and replaced it with obligation and frustration; and (3) “Coping strategies and informal support,” reflecting quiet resilience through self-regulation, peer solidarity, and humane leadership. Many participants framed their endurance as an act of moral defiance rather than passive resignation. Conclusions: These findings suggest that RT burnout reflects not individual failure but a structural outcome of sustained strain and deficits in reciprocity. Burnout emerges as an institutional crisis in which therapists remain deeply committed to patient care while being pushed toward professional collapse by systemic neglect. Culturally informed, system-level interventions are urgently needed to preserve this essential workforce.